Clinical trials: Multiple Cancer
Multiple Myeloma
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory…
- Trial name
- OPTIMISMM (NCT01734928)
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 321 sites in United States, Austria and 20 more
- Volunteers
- 559 people
- Sponsor
- Celgene
Solid Tumors, Homologous Recombination Repair Gene Mutation
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)
This study is a Phase 1b/2a basket trial to assess safety and efficacy of IDX-1197 in patients with HRR mutation. There are two parts to this study: Phase 1b, IDX-1197 dose-selection study to determine RP2D and Phase 2a…
- Conditions
- Solid Tumors, Homologous Recombination Repair Gene Mutation, Homologous Recombination Deficiency
- Trial name
- VASTUS (NCT04174716)
- Testing
- IDX-1197
- Where
- 19 sites in South Korea
- Volunteers
- 108 people
- Sponsor
- Idience Co., Ltd.
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor…
- Trial name
- CAURAL (NCT02454933)
- Testing
- AZD9291, MEDI4736
- Where
- 13 sites in Canada, South Korea and 1 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Cancer, Pain
Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
This study is to evaluate the safety and tolerability of oxycodone control-released (CR) and/or immediate-released (IR) use in patients with moderate to severe cancer pain in a 3-months period in Taiwan.
- Trial name
- STOP Pain (NCT03176121)
- Testing
- Oxycodone
- Where
- 10 sites in Taiwan
- Volunteers
- 73 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Relapsed or Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
- Trial name
- NCT03464916
- Testing
- CAR2 Anti-CD38 A2 CAR-T Cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
Colonic Neoplasms, Crohn Disease
Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy
The primary objective of this study is to retrospectively compare the perioperative and short-term (discharge through 30 days) outcomes of intracorporeal and extracorporeal anastomosis in minimally invasive right colectomies for…
- Trial name
- NCT03019016
- Testing
- Right Colectomy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Intuitive Surgical
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 30 sites in France, Greece and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumours, Small Cell Lung Cancer
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy…
- Trial name
- NCT04434482
- Testing
- IMP4297(senaparib)
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 59 people
- Sponsor
- Impact Therapeutics, Inc.
Neuroblastoma
Oral Liquid 13-cis-retinoic Acid (13-CRA)
An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.
- Trial name
- My-CRA (NCT03291080)
- Testing
- Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA
- Where
- 10 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Nova Laboratories Limited
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Thyroid Nodule, Thyroid Cancer
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
The purpose of this study is to evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features
- Trial name
- NCT05025046
- Testing
- Thyroscan
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Rigen Biotech
Breast Cancer
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to…
- Trial name
- NCT00330317
- Testing
- letrozole
- Where
- 20 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, maximum tolerated dose, and overall response rate of tivozanib (AV-951) and paclitaxel in a breast cancer.
- Trial name
- NCT00717340
- Testing
- tivozanib (AV-951) + paclitaxel
- Where
- 3 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Gastric Cancer
Single Patient Classifier (SPC) Prediction for Stage II and III Advanced Gastric Cancer
A retrospective, multi-center, single-blind, pivotal trial to assess clinical equivalence with stage II and III advanced gastric cancer based on the 6th and 8th of the AJCC
- Trial name
- SPRINT (NCT04600518)
- Testing
- nProfiler I Stomach Cancer Assay Kit
- Where
- South Korea
- Volunteers
- 2,047 people
- Sponsor
- Novomics. Co., Ltd.
Multiple Myeloma
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
This study aims to assess the efficacy and safety of pomalidomide in combination with low-dose dexamethasone in Chinese patients with relapsed and refractory multiple myeloma.
- Trial name
- NCT02916420
- Testing
- Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cancer, Metabolic Disease
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites…
- Conditions
- Cancer, Metabolic Disease, Aneurysm, Neurologic Disorder
- Trial name
- Hercules (NCT06212479)
- Testing
- MRI Scan
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Hercules
Solid Tumor, Metastatic Cancer
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid…
- Conditions
- Solid Tumor, Metastatic Cancer, Unresectable Solid Tumor, Recurrent Solid Tumor
- Trial name
- Tumorad (NCT06184035)
- Testing
- [177Lu]Lu-SN201
- Where
- 2 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Spago Nanomedical AB
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Multiple Myeloma
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
- Trial name
- CHAMPION 2 (NCT01980589)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
Anifrolumab Malignancy and Serious Infections Study
This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population…
- Trial name
- SIMA (NCT07000110)
- Testing
- Anifrolumab
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 3,506 people
- Sponsor
- AstraZeneca